MetaCap

Harmony Biosciences (HRMY) vs Zymeworks (ZYME)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Zymeworks (ZYME) has outperformed Harmony Biosciences (HRMY) over the past year, gaining 8.8% versus a loss of 5.0%. Over five years, ZYME leads with a +34.1% price change compared with -13.2% for HRMY. Harmony Biosciences is the larger company by market cap ($1.91 billion vs $1.81 billion), about 1.1 times the size, while Zymeworks is growing revenue faster (+38.9% vs +21.5%).

On valuation, Harmony Biosciences trades at a lower forward P/E (5.4x vs 55.0x for Zymeworks). Harmony Biosciences converts more of its revenue into profit, with a net margin of 18.3% versus -76.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

HRMY-5.01%ZYME+8.83%
+34%+4%-25%
Nov 21, 20251 yearNov 20, 2026
HRMY-15.92%ZYME+31.95%
+63%-10%-82%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

HRMY versus ZYME key metrics
MetricHRMYZYME
Share price$32.59$26.14
Market cap$1.91B$1.81B
1-day change-1.18%-2.68%
YTD return-12.91%-0.72%
1-year return-5.01%+8.83%
5-year return-13.21%+34.05%
P/E ratio (TTM)10.7949.32
Forward P/E5.3754.95
EPS (TTM)$3.02$0.53
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$868.45M$105.97M
Revenue growth (YoY)+21.51%+38.87%
Net income (latest FY)$158.69M$-81.13M
Gross margin77.16%—
Operating margin24.00%-87.34%
Net margin18.27%-76.56%
52-week high$43.49$31.97
52-week low$25.90$21.52
Distance from 52-week high-25.06%-18.24%
Analyst consensusbuystrong_buy
Avg. price target upside+47.53%+65.61%
Average volume1.01M1.09M
Shares outstanding58.72M68.70M
Employees293279
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ZYME has outperformed HRMY by 13.8 percentage points over the past year.
  • Zymeworks trades at a higher earnings multiple (49.3x vs 10.8x trailing P/E).
  • Harmony Biosciences is more profitable, keeping 18.3 cents of every revenue dollar as net income versus -76.6 cents for Zymeworks.
  • Zymeworks grew revenue faster in its latest fiscal year (+38.87% vs +21.51%).

About Harmony Biosciences

HRMY stock →

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.

Health Care · Biotechnology: Pharmaceutical Preparations · 293 employees

About Zymeworks

ZYME stock →

Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform.

Health Care · Biotechnology: Pharmaceutical Preparations · 279 employees

HRMY vs ZYME FAQ

Which is bigger, Harmony Biosciences or Zymeworks?

Harmony Biosciences (HRMY) is larger, with a market capitalization of $1.91B compared with $1.81B for Zymeworks (ZYME).

Which stock has performed better over the past year, HRMY or ZYME?

ZYME returned +8.83% over the past 12 months, compared with -5.01% for HRMY (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, HRMY or ZYME?

HRMY has the lower trailing P/E at 10.8, versus 49.3 for ZYME. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Are Harmony Biosciences and Zymeworks in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons